Graypoint LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 19.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,707 shares of the company’s stock after acquiring an additional 3,023 shares during the period. Graypoint LLC’s holdings in Johnson & Johnson were worth $3,096,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Peak Asset Management LLC raised its stake in shares of Johnson & Johnson by 9.3% in the 1st quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after buying an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Johnson & Johnson by 0.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock worth $116,071,000 after buying an additional 6,836 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its stake in shares of Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock worth $140,050,000 after buying an additional 161,687 shares in the last quarter. Tekla Capital Management LLC raised its stake in shares of Johnson & Johnson by 12.8% in the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock worth $111,876,000 after buying an additional 82,100 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC raised its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 80,179 shares of the company’s stock worth $13,271,000 after buying an additional 562 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $157.64 on Monday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The business has a 50-day moving average of $164.30 and a two-hundred day moving average of $162.40. The stock has a market capitalization of $409.70 billion, a P/E ratio of 31.91, a P/E/G ratio of 3.19 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on JNJ. Atlantic Securities boosted their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Morgan Stanley cut their target price on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 31st. Wells Fargo & Company cut their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research report on Thursday, August 31st. Credit Suisse Group boosted their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, Raymond James cut their target price on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $171.06.
Insider Buying and Selling
In related news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Invest in Toy Stocks
- How To Find Value Stocks Using This Simple Filtering Method
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 10/2 – 10/6
- Crypto vs Stocks: How to Choose Your Investments
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
